“I believe you should count your blessings that
Post# of 148331
Your inexperience as an investor and someone who is incapable of doing proper research is clearly demonstrated in your post and the quote above. Yes, COVID19 made leronlimab worth much more in the past 6 months than it was ever worth before, but that doesn’t discount the potential of the drug prior to that.
I loaded up big time in the .30s and .40s when early cancer results were being released and I still believe that cancer will be the biggest and possibly the most profitable for leronlimab. Saying that those who have been here awhile “should count our blessings” is ridiculous. Without COVID19 delays in the cancer trials, we would have data from potentially 30-40 cancer patients (Maybe more) and that would’ve pushed the PPS much higher..